Open: 1.16 Close: 1.27 Change: 0.11

Today's Summary

Andy Pasternak appointed Chairman of Context Therapeutics Board, succeeding Richard Berman, to drive company growth in t cell engager development. Pasternaks extensive background, including key roles in corporate strategy and a major acquisition at Horizon Therapeutic, adds significant value and expertise to the companys objectives. Context is building an innovative portfolio of innovative bispecific antibodies. Context Therapeutics to Appoint Dr. karen chagin, m.d. as chief medical officer. Dr. Chagin brings over a decade of leadership in clinical development and regulatory strategy for T cell therapies in solid tumors.